Bristol Myers Squibb's Earnings Highlight Legacy Portfolio Strength Amid Mixed Results
Bristol Myers Squibb reported Q1 revenue of $11.5 billion, a 3% increase year-over-year, driven largely by its legacy portfolio despite underperformance from newer drugs like Opdivo and Reblozyl. The results exceeded analyst estimates but were mixed due to the uneven performance across product lines.
Topics: clinical trials earnings pharmaceuticals stock performance